Softwr

Healthcare · head to head

DHIS2 vs PathAI

DHIS2 logo

DHIS2

Healthcare

Open source health information platform run from the University of Oslo and used by national ministries

From
Free
Rated
-
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-

The short version

  • Only DHIS2 has a free tier, so it costs nothing to try first.
  • Each has a real cost: DHIS2 the licence is free and the implementation is not; national rollouts routinely cost hundreds of thousands of dollars in configuration, hosting, training and support, and budgets built on the word free fail immediately.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: DHIS2 covers Aggregate data reporting, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which DHIS2 and PathAI actually diverge.

Attributes where DHIS2 and PathAI differ
AttributeDHIS2PathAI
Starting priceFreeOn request
Pricing modelOpen source, no licence feequote
Free tierYesNo
PlatformsWeb, Android, Self-hosted, CloudWeb

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in DHIS2

  • Aggregate data reporting
  • Tracker
  • Android capture app
  • Dashboards and analytics
  • Metadata packages
  • Data quality tools
  • GIS mapping
  • Interoperability

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

DHIS2

  • A ministry of health replacing paper monthly reporting from thousands of facilities with a national routine systemnot PathAI
  • A donor-funded HIV or tuberculosis programme that must report standard indicators across several districtsnot PathAI
  • A disease surveillance unit needing weekly case reporting with outbreak alerting and mappingnot PathAI
  • An NGO running individual patient follow-up in a programme where facilities are frequently offlinenot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot DHIS2
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot DHIS2
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot DHIS2
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot DHIS2

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

DHIS2

  • The licence is free and the implementation is not; national rollouts routinely cost hundreds of thousands of dollars in configuration, hosting, training and support, and budgets built on the word free fail immediately.
  • HISP UiO introduced a Shared Services Fee in 2025, so organisations that depend on DHIS2 are now being asked for an annual contribution that did not previously exist in their plans.
  • Development funding comes from a small set of donors including Norad, the Global Fund and the Gates Foundation, which concentrates the platform's long-term direction in the priorities of those funders.
  • Implementation capability is concentrated in regional HISP groups, so a country whose local HISP group is overstretched has few alternative suppliers with equivalent expertise.
  • Analytics performance depends heavily on how metadata was designed at the outset, and a poorly structured initial configuration produces slow dashboards and bad indicator definitions that are painful to correct years later.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

DHIS2

Free
  • DHIS2 softwareFree
    • BSD licence
    • All modules including Tracker
    • No user or facility limits
  • Shared Services Fee$undefined/year
    • Voluntary annual contribution introduced by HISP UiO
    • Funds shared global infrastructure and platform sustainability
    • Amount agreed with the HISP Centre
  • Implementation and support$undefined/year
    • Delivered by regional HISP groups or private implementers
    • Configuration, metadata design, hosting, training and support
    • Quoted per programme, commonly the dominant cost

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose DHIS2 if

  • You need aggregate data reporting.
  • You want to start without paying.
  • You work on Web, Android, Self-hosted, Cloud.
  • You also want tracker.

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.

Questions people ask

Is DHIS2 or PathAI better?
Neither clearly leads. DHIS2 starts at Free and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, DHIS2 or PathAI?
DHIS2 has a free tier; the other does not. Paid plans start at Free for DHIS2 and On request for PathAI.
Does DHIS2 or PathAI run on more platforms?
DHIS2 runs on Web, Android, Self-hosted, Cloud. PathAI runs on Web.
Can I use DHIS2 for free?
Yes. DHIS2 has a free tier, so you can try it without paying. PathAI starts at On request.
What is DHIS2 best used for?
DHIS2 is most often used for a ministry of health replacing paper monthly reporting from thousands of facilities with a national routine system, a donor-funded hiv or tuberculosis programme that must report standard indicators across several districts, a disease surveillance unit needing weekly case reporting with outbreak alerting and mapping, an ngo running individual patient follow-up in a programme where facilities are frequently offline. Of those, a ministry of health replacing paper monthly reporting from thousands of facilities with a national routine system and a donor-funded hiv or tuberculosis programme that must report standard indicators across several districts are not what PathAI is typically brought in for.
What can DHIS2 do that PathAI cannot?
DHIS2 covers Aggregate data reporting, Tracker, Android capture app, Dashboards and analytics. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

DHIS2: Who owns and develops DHIS2?

The HISP Centre at the University of Oslo, funded by donors including Norad, the Global Fund, the Gates Foundation and Wellcome.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

DHIS2: Is DHIS2 free?

The software is free under a BSD licence. Implementation, hosting, training and support are not, and are the dominant cost.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

DHIS2: What is the Shared Services Fee?

A voluntary annual contribution introduced by HISP UiO in 2025 to fund shared global infrastructure and long-term platform sustainability.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

DHIS2: Can I buy commercial support?

Yes, from regional HISP groups or private implementers such as Devotta, which is contracted by HISP UiO for core platform development and also works independently.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

Other head to heads